Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$225.30M+169.35%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mikhael Nassif
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 2,636
- Beta
- 1.76
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.51
Financials
Revenue
$225.30M+169.4%Net Income
$-11.30M-214.4%EBITDA
$36.80M+96.7%Free Cash Flow
$-9.47M-156.3%EPS (diluted)
$-0.05-151.3%Shares Outstanding (diluted)
217.70M+113.9%Operating Expenses
$104.70MCash & Debt
$185.50MReturn of Capital
$0.00Revenue by Segment (annual)
$870.40MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $870.40M | $-7.90M | $-0.04 |
| 2025 | $894.66M | $-1.09B | $-5.03 |
| 2024 | $924.22M | $-9.42M | $-0.04 |
| 2023 | $822.45M | $-22.87M | $-0.12 |
| 2022 | $527.16M | $48.31M | $0.45 |
| 2021 | $468.46M | $60.88M | $0.57 |
| 2020 | $418.17M | $59.48M | $0.57 |
| 2019 | $414.19M | $60.18M | $0.58 |
| 2018 | $397.93M | $63.15M | $0.61 |
| 2017 | $358.28M | $43.79M | $0.43 |
| 2016 | $321.27M | $36.56M | $0.36 |
| 2015 | $283.07M | $33.53M | $0.34 |
| 2014 | $247.41M | $28.16M | $0.29 |
| 2013 | $207.53M | $27.19M | $0.28 |
Valuation
NEOGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
0-100.00%Social Signal Score
Mentions (12)
- Newsbusinesswire.com·1d ago·Negative
NEOG Investors Have Opportunity to Join Neogen Corporation Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $NEOG--NEOG Investors Have Opportunity to Join Neogen Corporation Fraud Investigation with SBS Law.
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Neogen Shareholders Approve Board Elections, Pay and Equity Plan Amendments Neogen NASDAQ: NEOG shareholders approved all five proposals presented at the company's 2026 annual meeting, including the election of three directors, advisory approval of executive compensation, and amendments to the company's equity incentive and employee stock purchase plans.
View source ↗ - Newszacks.com·4d ago·Neutral
Unlocking Q1 Potential of Neogen (NEOG): Exploring Wall Street Estimates for Key Metrics Evaluate the expected performance of Neogen (NEOG) for the quarter ended August 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newszacks.com·4d ago·Neutral
Neogen Stock Rallies 83% YTD: What's Driving the Surge? NEOG's 83% YTD rally reflects Food Safety momentum, Petrifilm expansion, solutions-based selling and a growing product pipeline.
View source ↗ - Newsbusinesswire.com·5d ago·Negative
Securities Fraud Investigation Into Neogen Corporation (NEOG) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEOGEN CORPORATION (NEOG), CLICK HERE TO INQUIRE ABOUT PO…
View source ↗ - Newsbenzinga.com·6d ago·Negative
Why is Neogen Stock Trading Lower on Tuesday? The U.S. Food and Drug Administration (FDA) issued a formal warning letter to Mike Nassif, president and CEO of Neogen Corp (NASDAQ:NEOG), related to Neogen Vet's HYCOAT (Hyaluronate Sodium Sterile Solution).
View source ↗ - Newsbenzinga.com·11d ago·Negative
Neogen Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Neogen Corporation (NASDAQ:NEOG) will release earnings for its first quarter after the closing bell on Tuesday, Oct. 6.
View source ↗ - Newsbusinesswire.com·20d ago·Negative
Neogen Announces First-Quarter Earnings Release Date LANSING, Mich.--(BUSINESS WIRE)--Neogen® Corporation (NASDAQ: NEOG) will issue its first-quarter earnings release after the closing of the market on October 6, 2026. Executives from the company will host a webcast and conference call beginning at 4:30 p.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-833-461-5787 International: (+1) 626-884-3620 Conference ID: 323 …
View source ↗ - Newszacks.com·25d ago·Neutral
Is This the Right Time to Add Neogen Stock to Your Portfolio? NEOG advances product innovation and recovers Animal Safety operations, but high debt and intense competition remain key risks.
View source ↗ - Newszacks.com·35d ago·Positive
Neogen Surges 102.8% in a Year: What's Driving the Rally? NEOG shares gain 102.8% in a year as R&D investments, Food Safety growth and improving Animal Safety conditions fuel momentum despite key risks.
View source ↗ - Newszacks.com·42d ago·Positive
Neogen (NEOG) is a Great Momentum Stock: Should You Buy? Does Neogen (NEOG) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·55d ago·Neutral
Surging Earnings Estimates Signal Upside for Neogen (NEOG) Stock Neogen (NEOG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗
Earnings
Tue, Oct 6(today)
Consensus estimate $0.05 per share
Typical surprise +42.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.09 vs $0.06beat
- Thu, Apr 9$0.09 vs $0.04beat
- Thu, Jan 8$0.10 vs $0.07beat
- Thu, Oct 9$0.04 vs $-0.07beat
- Mon, Jul 28$-2.82 vs $0.08miss
- Wed, Apr 9$-0.05 vs $0.13miss
Estimates and results for NEOG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NEOG officers and directors.
- Bought
- $7k
- Sold
- —
6 trades
0 trades
- Nassif Mikhealbought
- Nassif Mikhealbought
- Nassif Mikhealbought
- Nassif Mikhealbought
- Nassif Mikhealbought
- Nassif Mikhealbought
94 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Greg Gianfortehouse · MT00 · disclosed Nov 9, 2020 (27d later)Sell$1,001 - $15,000
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (308d later)Sell$1,001 - $15,000
- Greg Gianfortehouse · MT00 · disclosed Jul 1, 2019 (19d later)Buy$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.